

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

NCI-H1975

RRID:CVCL_1511

Type: Cell Line

Proper Citation

RRID:CVCL_1511

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1511

Proper Citation: RRID:CVCL_1511

Description: Cell line NCI-H1975 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:8806092](#), [PMID:17332333](#), [PMID:18083107](#), [PMID:19727395](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:21498706](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25008024](#), [PMID:25483995](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26202522](#), [PMID:26554430](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27835594](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30710758](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32351780](#), [PMID:35117401](#), [PMID:35839778](#), [PMID:39061985](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1975

Synonyms: H1975, H-1975, NCIH1975

Cross References: BTO:BTO_0004824, CLO:CLO_0008035, EFO:EFO_0002271, CLDB:cl7204, AddexBio:C0016013/4946, ArrayExpress:E-MTAB-38, ArrayExpress:E-

MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5908, BCRJ:0352, BioGRID_ORCS_Cell_line:958, BioSample:SAMN03471753, BioSample:SAMN03472594, BioSample:SAMN10988259, cancercellines:CVCL_1511, CCRID:1101HUM-PUMC000252, CCRID:3101HUMSCSP597, CCRID:3101HUMTCHu193, Cell_Model_Passport:SIDM00759, ChEMBL-Cells:ChEMBL3307601, ChEMBL-Targets:ChEMBL614348, CLS:305067, Cosmic:687808, Cosmic:903607, Cosmic:924244, Cosmic:930487, Cosmic:1028949, Cosmic:1047098, Cosmic:1128244, Cosmic:1146894, Cosmic:1154595, Cosmic:1336879, Cosmic:1513408, Cosmic:1571739, Cosmic:1609518, Cosmic:1741781, Cosmic:1795297, Cosmic:1802294, Cosmic:1995548, Cosmic:2042865, Cosmic:2125194, Cosmic-CLP:924244, DepMap:ACH-000587, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:924244, GEO:GSM108829, GEO:GSM108830, GEO:GSM206481, GEO:GSM253304, GEO:GSM434293, GEO:GSM513951, GEO:GSM514336, GEO:GSM782116, GEO:GSM794340, GEO:GSM817094, GEO:GSM887393, GEO:GSM888471, GEO:GSM1374716, GEO:GSM1670203, Hysigen:TCH-C276, IARC_TP53:27189, ICLC:HTL06001, IGRhCellID:NCIH1975, KCB:KCB 2014034YJ, LiGeA:CCL_396, LINCS_LDP:LCL-1663, PharmacDB:NCIH1975_1053_2019, PRIDE:PXD001548, PRIDE:PXD002224, PRIDE:PXD011315, PRIDE:PXD015270, PRIDE:PXD030304, Progenetix:CVCL_1511, PubChem_Cell_line:CVCL_1511, Ubigene:YC-C106, Wikidata:Q54907891

ID: CVCL_1511

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260829T234731+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1975.

No alerts have been found for NCI-H1975.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1726 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Li P, et al. (2026) High-throughput identification of endogenous biomolecular condensates and phase-separating proteins. Nature protocols.

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. bioRxiv : the preprint server for biology.

Kim G, et al. (2026) Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor-Ligand Interactions. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76039.

Nishimura J, et al. (2026) Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer. *Molecular oncology*.

Lin X, et al. (2026) Repurposed ethoxzolamide reprograms antitumor immunity through γ -TrCP-dependent PD-L1 ubiquitination. *Cell reports. Medicine*, 7(7), 102920.

Eu JQ, et al. (2026) Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers. *NPJ precision oncology*, 10(1).

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. *Molecular cell*, 86(5), 954.

Ma C, et al. (2026) Effect of isoginkgetin on targeting methylenetetrahydrofolate dehydrogenase 2 to induce ROS-mediated apoptosis in non-small cell lung cancer. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 159, 158425.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1835.

Kanemura H, et al. (2026) Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. *Cancer research communications*, 6(4), 728.

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. *Cell death & disease*, 17(1).

Liao J, et al. (2026) Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. *Cancer cell*, 44(7), 1401.

Criscuolo D, et al. (2026) KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. *Apoptosis : an international journal on programmed cell death*, 31(8).

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Ma X, et al. (2026) UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma. *Cell reports*, 45(4), 117154.

Jiang H, et al. (2026) HIF-1 α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance. *Drugs in R&D*, 26(1), 101.

Xu Y, et al. (2026) KCTD10 weakens m6A modification of IL-11 in a ubiquitin-dependent manner to repress tumour immune escape in lung adenocarcinoma. *British journal of pharmacology*, 183(16), 4778.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. *Cell reports*, 45(6), 117427.

Bontekoe E, et al. (2026) FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. *Cancer immunology research*, 14(6), 958.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.